{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:44:10Z","timestamp":1790790250246,"version":"4.1.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.clml.2021.03.015","type":"journal-article","created":{"date-parts":[[2021,4,23]],"date-time":"2021-04-23T04:53:51Z","timestamp":1619153631000},"page":"545-548","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Cardiopulmonary exercise testing in patients with Cardiac Amyloidosis"],"prefix":"10.1016","volume":"21","author":[{"given":"Divaya","family":"Bhutani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhana","family":"Latif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rochelle L.","family":"Goldsmith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil E.","family":"Saith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus Y.","family":"Mapara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajshekhar","family":"Chakraborty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Lentzsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathew S.","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2021.03.015_bib0001","doi-asserted-by":"crossref","first-page":"5124","DOI":"10.1182\/blood-2013-01-453001","article-title":"Systemic light chain amyloidosis: an update for treating physicians","volume":"121","author":"Merlini","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.03.015_bib0002","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.1200\/JCO.2004.03.029","article-title":"Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis","volume":"22","author":"Dispenzieri","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.03.015_bib0003","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1161\/01.CIR.0000068314.02595.B2","article-title":"Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis","volume":"107","author":"Palladini","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.clml.2021.03.015_bib0004","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1016\/S0140-6736(03)13396-X","article-title":"Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins","volume":"361","author":"Dispenzieri","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2021.03.015_bib0005","doi-asserted-by":"crossref","first-page":"3854","DOI":"10.1182\/blood-2005-11-4385","article-title":"Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL","volume":"107","author":"Palladini","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.03.015_bib0006","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1200\/JCO.2011.37.7614","article-title":"New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes","volume":"30","author":"Palladini","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.03.015_bib0007","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","article-title":"A new staging system for cardiac transthyretin amyloidosis","volume":"39","author":"Gillmore","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clml.2021.03.015_bib0008","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1373\/clinchem.2006.080234","article-title":"Comparison of brain natriuretic peptide (BNP) and amino-terminal ProBNP for early diagnosis of heart failure","volume":"53","author":"Emdin","year":"2007","journal-title":"Clin Chem"},{"key":"10.1016\/j.clml.2021.03.015_bib0009","first-page":"1285","article-title":"Cardiopulmonary exercise testing and its application","volume":"93","author":"Albouaini","year":"2007","journal-title":"Heart"},{"key":"10.1016\/j.clml.2021.03.015_bib0010","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1016\/j.jacc.2017.08.012","article-title":"Cardiopulmonary exercise testing: what is its value?","volume":"70","author":"Guazzi","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clml.2021.03.015_bib0011","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1136\/pgmj.75.886.453","article-title":"The role of exercise testing in the evaluation and management of heart failure","volume":"75","author":"Wright","year":"1999","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.clml.2021.03.015_bib0012","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.ijcard.2018.12.069","article-title":"Conversion formula from B-type natriuretic peptide to N-terminal proBNP values in patients with cardiovascular diseases","volume":"280","author":"Kasahara","year":"2019","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.clml.2021.03.015_bib0013","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jacc.2017.09.1157","article-title":"Myocardial contraction fraction: a volumetric measure of myocardial shortening analogous to strain","volume":"71","author":"Matthews","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clml.2021.03.015_bib0014","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.1200\/JCO.2004.03.029","article-title":"Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis","volume":"22","author":"Dispenzieri","year":"2004","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.clml.2021.03.015_bib0015","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1182\/blood-2016-11-751628","article-title":"Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death","volume":"129","author":"Muchtar","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.03.015_bib0016","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.115.002877","article-title":"Subtype-specific interactions and prognosis in cardiac amyloidosis","volume":"5","author":"Sperry","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.clml.2021.03.015_bib0017","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1182\/blood.V116.21.3021.3021","article-title":"Increases in B-type natriuretic peptide (BNP) during treatment with lenalidomide In AL amyloidosis","volume":"116","author":"Tapan","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.03.015_bib0018","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1080\/13506129.2018.1496077","article-title":"Peak V'O2 is an independent predictor of survival in patients with cardiac amyloidosis","volume":"25","author":"Hein","year":"2018","journal-title":"Amyloid"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265021001543?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265021001543?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:36:03Z","timestamp":1761870963000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265021001543"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":18,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["S2152265021001543"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2021.03.015","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiopulmonary exercise testing in patients with Cardiac Amyloidosis","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2021.03.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}